Abstract:There is considerable interest in developing new SERMs as multifunctional agents in women's health. Development of dual selective estrogen receptor modulators/VEGFR-2 inhibitors (SERMs/V-2I) has been an attractive strategy for the discovery of new breast cancer therapeutic agents. Our previous efforts led to the preparation of a series of 3-aryl-4-anilino-2H-chromen-2-ones endowed with potent estrogen receptor binding affinity and anti-proliferative efficacy. In this study, various structurally related 3-aryl-4-anilino/aryloxy-2H-chromen-2-one analogues were rationally designed, synthesized and evaluated as a new chemo-type of dual ERα and VEGFR-2 inhibitors. Most of the derivatives exhibited potent activities in both enzymatic and cellular assays. SAR investigation revealed that introducing of bioisosteric O atom at the C-4 position of coumarin scaffold is beneficial to improve the inhibitory potency, especially in ERα binding affinity assay. Furthermore, most of the piperidyl substituted compounds showed better inhibitory activity against MCF-7 and Ishikawa cells than lead compounds BL-18d, tamoxifen and Vandetanib. Optimization of the hit compound, identified in an ERα binding affinity assay, led to compound 42d, exhibiting an IC50 for ERα binding affinity of 2.19 μM while retaining an excellent inhibition on VGFR-2 as well as a potent suppression on the growth of angiogenesis-related cells. In RT-PCR assay, 42d exerted significantly antiestrogenic property via suppressing the expression of progesterone receptor (PgR) mRNA in MCF-7 cells, which was consistent with the ERα antagonistic property of a selective estrogen receptor modulator. Further mechanism investigation demonstrated that compound 42d could inhibit the activation of VEGFR-2 and subsequent signaling transduction of Raf-1/MAPK/ERK pathway in MCF-7 cells. All these results together with molecular modeling studies open a new avenue for the development of multifunctional agents targeting ERα and VEGFR-2 in the therapy of some breast cancers.

Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells.

Rational Design and Optimization of Selenophenes with Basic Side Chains As Novel Potent Selective Estrogen Receptor Modulators (serms) for Breast Cancer Therapy.

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.

Synthesis and Structure–activity Relationships of Novel Hybrid Ferrocenyl Compounds Based on a Bicyclic Core Skeleton for Breast Cancer Therapy

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Discovery of Novel 2H-Chromene-3-carbonyl Derivatives As Selective Estrogen Receptor Degraders (serds): Design, Synthesis and Biological Evaluation.

Discovery of novel quinoline scaffold selective estrogen receptor degraders (SERDs) for treatment of ER positive breast cancer with enhanced antiproliferative bioactivity through immunogenic cell death (ICD) effects

Synthesis and Biological Evaluation of 3-Aryl-quinolin Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening.

Discovery of Thiochroman Derivatives as Potent, Oral Selective Estrogen Receptor Degraders and Antagonists for the Treatment of Endocrine-Resistant Breast Cancer

Novel SERMs Based on 3-Aryl-4-aryloxy-2h-chromen-2-one Skeleton - A Possible Way to Dual ERα/VEGFR-2 Ligands for Treatment of Breast Cancer.

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: an Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators Against Endocrine-Resistant Breast Cancer.

Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer

Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy

Novel Class of 7-Oxabicyclo[2.2.1]heptene Sulfonamides with Long Alkyl Chains Displaying Improved Estrogen Receptor Α Degradation Activity.

Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer

Discovery of Thieno[2,3-e]indazole Derivatives As Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

A New Class of 1,3,5-Triazine-based Selective Estrogen Receptor Degraders (serds): Lead Optimization, Molecular Docking and Dynamic Simulation.

Synthesis, structure characterization and preliminary biological evaluation of novel 5-alkyl-2-ferrocenyl-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives